Aspirin Use Among Saudi Adults: The Prevalence and Users' Characteristics

Overview

Journal Saudi Pharm J

Specialty Pharmacy

Date 2022 May 9

PMID 35527833

Authors

Sultan Alghadeer

Abdulrahman M Alwhaibi

Abdulaziz Alhossan

Salmeen D Babelghaith

Abdullah M Mubarak

Sana Samreen

Nouf N Alameel

Noura N Aljabali

Mohamed N Al-Arifi

Affiliations

Soon will be listed here.

Abstract

Introduction: Despite the public routine use of aspirin as cardio-prophylaxis agent, its use is only recommended in particular situations, and not as usual primary prevention. Only few local studies investigate the use of aspirin in patients with certain diseases, but not within the public population. The purpose of this study was to evaluate the prevalence of aspirin use and identify the demographic and clinical characteristics among Saudi users.

Methodology: A cross-sectional study targeting Saudi adults in Saudi Arabia was conducted over a period of four months in 2021 using online Google forms. The study collected data to assess the prevalence of use, use of aspirin according to prevention type, users' characteristics and comorbidities. Additionally, a self-assessment of knowledge, perception, reasons and attitude towards aspirin use among Saudi adults was conducted. A chi-square test was used to determine the association between the variables. A P-value ≤ 0.05 was considered statistically significant.

Results: The prevalence of aspirin use was 47%. Regarding the self-assessed aspirin knowledge, the majority of the respondents (n = 481; 62.4 %) found to have good knowledge. Less than half of the participants (n = 341; 44%) use aspirin as primary prevention agent while only 23 participants (2.9%) use aspirin as secondary prevention agent. There was a significant difference between gender and user type (p = 0.001). With regards to comorbidities, hypertension, hyperlipidemia, diabetes, and obesity were common among the primary users of aspirin. Significant associations were found (p = 0.001) between participant's user type and the following characteristics such as smoking status, past medical history, presence of comorbidities.

Conclusion: Aspirin use is commonly prevalent Saudi population with good level of knowledge of the therapy; however, its popular use as primary preventive agent for CVD may necessitate medical advice based on the level of cardiovascular risk.

Citing Articles

Hypertensive Disorders of Pregnancy in Saudi Arabia: Evaluating Maternal and Neonatal Risks, Outcomes, and Aspirin Prophylaxis: A Review Article.

Jayousi T, Taha M, Jaan S, Aljabri A, Banaji S, Ishqi R Cureus. 2024; 16(9):e68737.

PMID: 39371852 PMC: 11454759. DOI: 10.7759/cureus.68737.

The current view of potentially inappropriate medications (PIMs) among older adults in Saudi Arabia: a systematic review.

Alotaibi F Front Pharmacol. 2024; 14:1325871.

PMID: 38186639 PMC: 10770872. DOI: 10.3389/fphar.2023.1325871.

References

Rodondi N, Cornuz J, Marques-Vidal P, Butler J, Hayoz D, Pecoud A . Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland. Prev Med. 2007; 46(2):137-44. DOI: 10.1016/j.ypmed.2007.08.006. View

Pignone M, Alberts M, Colwell J, Cushman M, Inzucchi S, Mukherjee D . Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American.... Diabetes Care. 2010; 33(6):1395-402. PMC: 2875463. DOI: 10.2337/dc10-0555. View

Stuntz M, Bernstein B . Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012-2015. Prev Med Rep. 2017; 5:183-186. PMC: 5219640. DOI: 10.1016/j.pmedr.2016.12.023. View

Abdelaziz H, Saad M, Pothineni N, Megaly M, Potluri R, Saleh M . Aspirin for Primary Prevention of Cardiovascular Events. J Am Coll Cardiol. 2019; 73(23):2915-2929. DOI: 10.1016/j.jacc.2019.03.501. View

de Gaetano G . Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001; 357(9250):89-95. DOI: 10.1016/s0140-6736(00)03539-x. View

Batais M, Almutairi K, Almigbal T, Alodhayani A, Alonazi W, Vinluan J . Recommendation of Aspirin-Guide App and Physicians Clinical Decision of Aspirin Use to Prevent CVD Among Diabetic Patients, Is there any Differences?. J Cardiovasc Pharmacol Ther. 2020; 26(2):158-164. DOI: 10.1177/1074248420958976. View

Williams C, Chan A, Elman M, Kristensen A, Miser W, Pignone M . Aspirin use among adults in the U.S.: results of a national survey. Am J Prev Med. 2015; 48(5):501-8. DOI: 10.1016/j.amepre.2014.11.005. View

Lugo A, Asciutto R, Bosetti C, Parazzini F, La Vecchia C, Gallus S . Regular use of aspirin for cardiovascular disease prevention in Italy. Prev Med. 2014; 63:48-51. DOI: 10.1016/j.ypmed.2014.03.005. View

Ridker P, Cook N, Lee I, Gordon D, Gaziano J, Manson J . A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352(13):1293-304. DOI: 10.1056/NEJMoa050613. View

10.

van Kruijsdijk R, Visseren F, Ridker P, Dorresteijn J, Buring J, van der Graaf Y . Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women. Heart. 2014; 101(5):369-76. PMC: 4536552. DOI: 10.1136/heartjnl-2014-306342. View

11.

Webster R, Heeley E, Peiris D, Bayram C, Cass A, Patel A . Gaps in cardiovascular disease risk management in Australian general practice. Med J Aust. 2009; 191(6):324-9. DOI: 10.5694/j.1326-5377.2009.tb02816.x. View

12.

Alkhail B, Iftikhar R, Shaikh A . Use of Aspirin and Statin as primary prevention for cardiovascular diseases. Pak J Med Sci. 2017; 32(6):1336-1339. PMC: 5216277. DOI: 10.12669/pjms.326.10615. View

13.

Arnett D, Blumenthal R, Albert M, Buroker A, Goldberger Z, Hahn E . 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 140(11):e596-e646. PMC: 7734661. DOI: 10.1161/CIR.0000000000000678. View

14.

Algra A, Rothwell P . Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012; 13(5):518-27. DOI: 10.1016/S1470-2045(12)70112-2. View

15.

Pignone M, Anderson G, Binns K, Tilson H, Weisman S . Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med. 2007; 32(5):403-407. DOI: 10.1016/j.amepre.2007.01.010. View

16.

Luepker R, Steffen L, Duval S, Zantek N, Zhou X, Hirsch A . Population Trends in Aspirin Use for Cardiovascular Disease Prevention 1980-2009: The Minnesota Heart Survey. J Am Heart Assoc. 2015; 4(12). PMC: 4845283. DOI: 10.1161/JAHA.115.002320. View

17.

Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N . Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008; 300(18):2134-41. DOI: 10.1001/jama.2008.623. View

18.

Fowkes F, Price J, Stewart M, Butcher I, Leng G, Pell A . Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010; 303(9):841-8. DOI: 10.1001/jama.2010.221. View

19.

Zhou Y, Boudreau D, Freedman A . Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf. 2013; 23(1):43-50. DOI: 10.1002/pds.3463. View

20.

Bibbins-Domingo K . Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016; 164(12):836-45. DOI: 10.7326/M16-0577. View